Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other di
Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Inflazome a couple of years after snapping up
Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.